Weill Cornell Lymphoma Program

09/03/2026

After finishing her fellowship at Weill Cornell Medicine, Dr. Evelyn Orlando joined us as a faculty member this month and will be caring for patients with . An official warm welcome to the team! https://bit.ly/4xrCSOt

09/01/2026

Join us in welcoming the new head of our Weill Cornell Medicine program, Dr. Paul Hamlin! Dr. Hamlin brings decades of experience and we’re excited to have him leading our team. Learn more about him and make an appointment here: https://bit.ly/4gI2Xld

08/20/2026

Dr. John Allan spoke with OncLive about how different treatment options compare to one another for chronic lymphocytic leukemia (CLL):

John N. Allan, MD, discusses data for fixed-duration regimens in chronic lymphocytic leukemia and their respective nuances.

08/17/2026

WATCH: Dr. Erin Mulvey discusses treatment data for first-line Bruton’s tyrosine kinase (BTK) inhibitors for chronic lymphocytic leukemia (CLL)

Erin Mulvey, MD, discusses real-world time to treatment discontinuation data for first-line zanubrutinib compared with other BTK inhibitors in CLL.

08/12/2026

Listen to Dr. John Allan on the OncLive On Air podcast where he discussed treatment regimens for chronic lymphocytic leukemia (CLL) and how to improve outcomes for high-risk patients:

John N. Allan, MD, discusses all things regarding fixed-duration regimens in CLL from a review of the most pivotal data for the topic.

05/05/2026

WATCH: Dr. Erin Mulvey discusses the changing treatment landscape for Richter Transformation, a rare condition where chronic lymphocytic leukemia ( ) or small lymphocytic (SLL) turns into a more aggressive form of lymphoma

At the 2026 LL&M Winter Symposium, Erin Mulvey, MD, discusses the evolving treatment landscape for Richter transformation.

05/01/2026

led by Dr. Jia Ruan and her collaborators aims to improve therapy options and survival rates for peripheral T-cell . Hear more from Dr. Ruan about this important work:

We sat down with Dr. Jia Ruan to learn more about her clinical research and how she thinks it will help lymphoma patients.

04/03/2026

Dr. Erin Mulvey spoke with Blood Cancers Today about how the phase 3 MURANO continues to inform targeted treatment approaches and management for chronic lymphocytic leukemia ( ):

The MURANO trial transformed CLL care. Explore 5 ways it drives venetoclax use, fixed-duration therapy, and personalized treatment today

03/31/2026

Watch Dr. Richard Furman discuss early findings from the CLL-17 looking at different treatment regimens for untreated chronic lymphocytic leukemia ( ): https://bit.ly/4v4CDs3 (cc: Oncology Learning Network)

Richard Furman, MD, discusses early results from the CLL-17 trial, underscoring the need for longer follow-up before defining optimal frontline strategies for treatment-naïve patients with chronic lymphocytic leukemia.

03/26/2026

Dr. Jia Ruan led research evaluating triplet combination therapy for previously untreated mantle cell (MCL). She spoke with OncLive about the key takeaways:

Acalabrutinib/lenalidomide in combination with rituximab or obinutuzumab generated uMRD6 CRs in previously untreated mantle cell lymphoma.